Published in J Cell Sci on April 20, 2010
MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene (2012) 2.03
Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett (2012) 1.73
The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med (2011) 1.52
Nuclear EGFR as a molecular target in cancer. Radiother Oncol (2013) 1.33
Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci (2012) 1.31
MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr (2013) 1.31
Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med (2010) 1.22
Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta (2011) 1.20
Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev (2012) 1.18
Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol (2013) 1.17
Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release (2014) 1.08
EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1. PLoS One (2012) 1.00
TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice. Oncogene (2012) 0.95
The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis (2014) 0.93
Receptor tyrosine kinases in the nucleus. Cold Spring Harb Perspect Biol (2013) 0.93
MUC1 contributes to BPDE-induced human bronchial epithelial cell transformation through facilitating EGFR activation. PLoS One (2012) 0.93
MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol (2013) 0.88
Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget (2015) 0.88
The MUC1 Ectodomain: A Novel and Efficient Target for Gold Nanoparticle Clustering and Vapor Nanobubble Generation. Theranostics (2012) 0.88
The MUC1 extracellular domain subunit is found in nuclear speckles and associates with spliceosomes. PLoS One (2012) 0.84
Altered Mucins (MUC) trafficking in benign and malignant conditions. Oncotarget (2014) 0.82
MUC1 Predicts Colorectal Cancer Metastasis: A Systematic Review and Meta-Analysis of Case Controlled Studies. PLoS One (2015) 0.82
Pseudomonas aeruginosa stimulates tyrosine phosphorylation of and TLR5 association with the MUC1 cytoplasmic tail through EGFR activation. Inflamm Res (2015) 0.80
Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. Oncotarget (2015) 0.80
Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer (2015) 0.79
Non-canonical signaling mode of the epidermal growth factor receptor family. Am J Cancer Res (2015) 0.79
Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression. Mol Ther (2013) 0.79
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. FEBS J (2015) 0.79
MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother Radiopharm (2011) 0.79
Autophagy is decreased in triple-negative breast carcinoma involving likely the MUC1-EGFR-NEU1 signalling pathway. Int J Clin Exp Pathol (2015) 0.79
Imaging of epidermal growth factor receptor on single breast cancer cells using surface-enhanced Raman spectroscopy. Anal Chim Acta (2014) 0.78
EGFs and ERBBs--brief history and prospects. Semin Cell Dev Biol (2010) 0.77
Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. Horm Cancer (2015) 0.76
Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta (2014) 0.76
MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res (2012) 0.76
Analysis of Epithelial Growth Factor-Receptor (EGFR) Phosphorylation in Uterine Smooth Muscle Tumors: Correlation to Mucin-1 and Galectin-3 Expression. Int J Mol Sci (2013) 0.76
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling). Biomolecules (2016) 0.75
Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors. Virchows Arch (2016) 0.75
Cigarette Smoke Mediates Nuclear to Cytoplasmic Trafficking of Transcriptional Inhibitor Kaiso through MUC1 and P120-Catenin. Am J Pathol (2016) 0.75
αPIX Is a Trafficking Regulator that Balances Recycling and Degradation of the Epidermal Growth Factor Receptor. PLoS One (2015) 0.75
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. Cell Death Differ (2017) 0.75
Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231. Sci Rep (2017) 0.75
Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol (2001) 7.22
gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science (2001) 4.90
Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol (2005) 4.48
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem (2001) 2.41
Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30
c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol (2002) 2.27
Nuclear import of the MUC1-C oncoprotein is mediated by nucleoporin Nup62. J Biol Chem (2007) 2.23
Cloning and sequencing of a human pancreatic tumor mucin cDNA. J Biol Chem (1990) 2.22
MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell (2006) 2.15
Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem (2006) 2.11
MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res (2009) 2.04
Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell (2007) 1.99
MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene (2004) 1.86
Understanding and treating triple-negative breast cancer. Oncology (Williston Park) (2008) 1.73
Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem (2003) 1.73
Nuclear Translocation of fibroblast growth factor (FGF) receptors in response to FGF-2. J Cell Biol (1996) 1.72
Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71
Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev (2007) 1.65
The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer (2001) 1.62
Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res (1995) 1.60
VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun (1999) 1.53
MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther (2003) 1.39
MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene (2006) 1.38
Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res (2003) 1.34
Differential detergent fractionation of isolated hepatocytes: biochemical, immunochemical and two-dimensional gel electrophoresis characterization of cytoskeletal and noncytoskeletal compartments. Electrophoresis (1994) 1.22
Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res (2009) 1.19
Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest (1998) 1.19
Mitogen-induced recruitment of ERK and MSK to SRE promoter complexes by ternary complex factor Elk-1. Nucleic Acids Res (2008) 1.18
Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res (2007) 1.16
The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core. J Biol Chem (2002) 1.15
Controlling protein compartmentalization to overcome disease. Pharm Res (2006) 1.15
The epithelial sialomucin, episialin, is sialylated during recycling. J Biol Chem (1993) 1.14
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res (2004) 1.13
The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. J Biol Chem (1996) 1.04
Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res (2006) 1.03
Heart-valve mesenchyme formation is dependent on hyaluronan-augmented activation of ErbB2-ErbB3 receptors. Nat Med (2002) 2.26
CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res (2005) 1.72
Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res (2011) 1.53
MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr (2013) 1.31
Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res (2009) 1.23
Transforming growth factor alpha dependent cancer progression is modulated by Muc1. Cancer Res (2007) 1.16
Detachment of captured cancer cells under flow acceleration in a bio-functionalized microchannel. Lab Chip (2009) 1.01
A high-performance microsystem for isolating circulating tumor cells. Lab Chip (2011) 0.99
Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat Anticancer Drug Discov (2010) 0.89
MUC1 can interact with adenomatous polyposis coli in breast cancer. Biochem Biophys Res Commun (2004) 0.84
CD44 Promotes Epithelial Mammary Gland Development and Exhibits Altered Localization during Cancer Progression. Genes Cancer (2011) 0.83
Pilot study on the effects of dietary conjugated linoleic acid on tumorigenesis and gene expression in PyMT transgenic mice. Carcinogenesis (2010) 0.82
Hugl1 and Hugl2 in mammary epithelial cells: polarity, proliferation, and differentiation. PLoS One (2012) 0.82
Cell receptor and surface ligand density effects on dynamic states of adhering circulating tumor cells. Lab Chip (2011) 0.81
Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression. Mol Ther (2013) 0.79
Matrix hyaluronan alters epidermal growth factor receptor-dependent cell morphology. Cell Adh Migr (2010) 0.76
MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res (2012) 0.76